tlr7 agonist bnt411
Generic: TLR7 agonist BNT411
tlr7 agonist bnt411: 1 clinical trial tracked.
tlr7 agonist bnt411 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about tlr7 agonist bnt411, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
Phase 1/2a, First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT411 as a Monotherapy in Patients With Solid Tumors and in Combination With Atezolizumab, Carboplatin and Etoposide in Patients With Chemotherapy-naïve Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Primary endpoint: Number of Participants With Dose Limiting Toxicities (DLTs)
Interventionalopen54 targetStarted 2020-06Completion 2024-0512 sites · Germany, Spain, United Kingdom, United StatesBioNTech SE